8-K: ANI Pharmaceuticals Reports Record Q4 and Full-Year 2024 Results, Raises 2025 Guidance

ANI Pharmaceuticals announced record fourth-quarter and full-year 2024 financial results, driven by strong performance in its Rare Disease and Generics businesses, and raised its 2025 financial guidance.

Summary

• ANI Pharmaceuticals reported record net revenues of $190.6 million for the fourth quarter of 2024, a 44.8% increase year-over-year.
• Rare Disease quarterly net revenue reached $87.0 million, including a record $59.4 million for Purified Cortrophin Gel, a 42.3% increase year-over-year.
• ILUVIEN and YUTIQ contributed $27.6 million in net revenues in their first full quarter of ownership following the acquisition of Alimera Sciences.
• Adjusted non-GAAP EBITDA for the quarter was a record $50.0 million, a 65.7% increase year-over-year.
• The company reported a diluted GAAP loss per share of $(0.55) and adjusted non-GAAP diluted earnings per share of $1.63.
• ANI raised its 2025 guidance, expecting net revenues of $756.0 million to $776.0 million and adjusted non-GAAP EBITDA of $190.0 million to $200.0 million.
• Adjusted non-GAAP diluted earnings per share guidance for 2025 is $6.12 to $6.49.
• Rare Disease net revenues are expected to represent 48% to 49% of total company net revenues in 2025.
• This includes Purified Cortrophin Gel net revenues of $265.0 million to $274.0 million, representing year-over-year growth of 33.8% to 38.3%.
• ILUVIEN and YUTIQ net revenues are projected to be $97.0 million to $103.0 million in 2025.
• Generics revenues increased 9.4% to $78.6 million during the quarter.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with record financial results, increased guidance, and strategic growth initiatives. The management's comments are optimistic, and the company appears to be well-positioned for future success.

Positives

• Record quarterly net revenues of $190.6 million, representing a 44.8% year-over-year increase.
• Significant growth in the Rare Disease segment, with $87.0 million in quarterly net revenue.
• Record quarterly net revenue for Purified Cortrophin Gel of $59.4 million, a 42.3% year-over-year increase.
• Successful integration of ILUVIEN and YUTIQ, contributing $27.6 million in net revenues in their first full quarter.
• Record quarterly adjusted non-GAAP EBITDA of $50.0 million, a 65.7% year-over-year increase.
• Increased 2025 guidance for net revenues and adjusted non-GAAP EBITDA.
• Generics revenues increased 9.4% to $78.6 million during the quarter.
• The company launched five new products during the quarter and 17 for the full year.
• ANI has made substantial progress toward increasing supply security for the ILUVIEN and YUTIQ franchise.
• ANI extended its partnership with Siegfried, its long-term supplier for ILUVIEN, through 2029, and contracted with Siegfried to upgrade equipment on the existing manufacturing line and significantly expand capacity through the addition of a second manufacturing line.
• ANI launched Prucalopride Tablets with 180 days of exclusivity in Q1 2025.

Negatives

• The company reported a diluted GAAP loss per share of $(0.55) for the fourth quarter of 2024.
• On a GAAP basis, gross margin decreased from 59.4% to 57.9%, primarily due to significant growth of royalty bearing products, including Cortrophin Gel, and amortization of the inventory fair value step up recognized in conjunction with the acquisition of Alimera.
• On a GAAP basis, research and development expenses increased 68.7% to $16.6 million due to expenses related to the NEW DAY and SYNCHRONICITY clinical trials, development of a Cortrophin Gel pre-filled syringe, and ongoing investment in generic R&D programs.
• On a GAAP basis, selling, general, and administrative expenses increased 56.8% to $69.7 million, resulting from a full quarter of expense associated with the ANI and Alimera combined ophthalmology sales force, continued investment in Rare Disease sales and marketing activities, increased employment-related costs, including incentive-based compensation tied to record 2024 financial performance, and an overall increase in activities required to support the growth of our business.

Risks

• The company's ability to achieve commercialization of approved products, including Cortrophin Gel, ILUVIEN, and YUTIQ, at levels of market acceptance that will continue to allow it to achieve profitability is uncertain.
• There are risks associated with completing or achieving the intended benefits of acquisitions and investments, including the acquisition of Alimera, in a timely manner or at all.
• The company's cash flow may be limited as a result of the indebtedness and liabilities incurred from the recent acquisition of Alimera.
• Delays and disruptions in production of approved products, increased costs, and potential loss of revenues may occur if the company needs to change suppliers due to the limited number of suppliers for raw materials.
• Delays or failure in obtaining and maintaining approvals by the FDA of the products the company sells pose a risk.
• Changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies could impact the company.
• Risks exist with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of products from both domestic and overseas sources due to supply chain disruptions or for any other reason.
• The ability of manufacturing partners to meet product demands and timelines is a risk.
• The impact of changes or fluctuations in exchange rates could affect the company.
• The company's ability to develop, license or acquire, and commercialize new products is uncertain.
• Obligations in agreements under which the company licenses, develops or commercializes rights to products or technology from third parties and the ability to maintain such licenses pose a risk.
• The level of competition the company faces and the legal, regulatory and/or legislative strategies employed by competitors to prevent or delay competition from generic alternatives to branded products could impact the company.
• The company's ability to protect its intellectual property rights is a risk.
• The impact of legislative or regulatory reform on the pricing for pharmaceutical products could affect the company.
• The impact of any litigation to which the company is, or may become, a party is a risk.
• The company's ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries is a risk.
• The company's ability to maintain the services of its key executives and other personnel is a risk.
• General business and economic conditions, such as inflationary pressures, geopolitical conditions including but not limited to the conflict between Russia and the Ukraine, the conflict in the Middle East, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies, could impact the company.

Future Outlook

ANI Pharmaceuticals raised its full-year 2025 guidance, expecting net revenues of $756 million to $776 million and adjusted non-GAAP EBITDA of $190 million to $200 million. Adjusted non-GAAP diluted earnings per share guidance for 2025 is $6.12 to $6.49. Rare Disease net revenues are expected to represent 48% to 49% of total company net revenues in 2025.

Management Comments

• Nikhil Lalwani, President and CEO of ANI, stated, 'We're thrilled to report another year of strong execution for ANI, capped by our record fourth quarter results, with total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS all finishing above our previously announced guidance for the full year.'
• Mr. Lalwani also noted that Cortrophin Gel generated nearly $200 million in sales during 2024, in just the third year since launch, and the Generics business delivered its third straight year of double-digit growth.
• Mr. Lalwani concluded, 'With our business off to a strong start in 2025, particularly Cortrophin Gel, Generics, and Brands, we are raising our 2025 guidance for total net revenues and adjusted non-GAAP EBITDA.'

Industry Context

ANI's focus on Rare Diseases and Generics aligns with industry trends towards specialized and cost-effective pharmaceutical solutions. The acquisition of Alimera Sciences and the expansion of the Cortrophin Gel market demonstrate a strategic effort to capitalize on niche markets with high growth potential. The company's U.S.-based manufacturing footprint provides a competitive advantage in terms of supply chain reliability and responsiveness.

Comparison to Industry Standards

• ANI's revenue growth of 44.8% in Q4 2024 significantly outpaces the average growth rate for the pharmaceutical industry.
• Companies like Teva Pharmaceutical Industries and Viatris, which focus on generic drugs, have seen more modest growth rates in recent years.
• ANI's focus on rare diseases positions it similarly to companies like Horizon Therapeutics, which have experienced rapid growth through the development and commercialization of specialized therapies.
• The adjusted non-GAAP EBITDA margin of ANI is comparable to other specialty pharmaceutical companies with a focus on high-value products.
• ANI's investment in R&D, particularly in generic R&D programs, is consistent with industry standards for companies seeking to maintain a robust pipeline of new products.

Stakeholder Impact

• Shareholders are likely to react positively to the strong financial results and increased guidance.
• Employees may benefit from increased job security and potential for bonuses due to the company's strong performance.
• Customers will continue to have access to the company's products and services.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its strong financial performance.

Next Steps

• The company plans to participate in upcoming investor conferences.
• The company expects FDA approval of the PAS in the second quarter of 2025 and plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of diabetic macular edema (DME) in the U.S.

Key Dates